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Neonatal and obstetric outcomes in
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Abstract
Background: To evaluate the neonatal and obstetric outcomes of pregnancies complicated by gestational diabetes
mellitus (GDM). Screening and treatment – diet-only versus additional insulin therapy – were based on the 2010
national Dutch guidelines.
Methods: Retrospective study of the electronic medical files of 820 singleton GDM pregnancies treated between
January 2011 and September 2014 in a university and non-university hospital. Pregnancy outcomes were compared
between regular care treatment regimens –diet-only versus additional insulin therapy- and pregnancy outcomes of
the Northern region of the Netherlands served as a reference population.
Results: A total of 460 women (56 %) met glycaemic control on diet-only and 360 women (44 %) required
additional insulin therapy. Between the groups, there were no differences in perinatal complications (mortality, birth
trauma, hyperbilirubinaemia, hypoglycaemia), small for gestational age, large for gestational age (LGA), neonate
weighing >4200 g, neonate weighing ≥4500 g, Apgar score <7 at 5 min, respiratory support, preterm delivery, and
admission to the neonatology department. Neonates born in the insulin-group had a lower birth weight compared
with the diet-group (3364 vs. 3467 g, p = 0.005) and a lower gestational age at birth (p = 0.001). However, birth
weight was not different between the groups when expressed in percentiles, adjusted for gestational age,
gender, parity, and ethnicity. The occurrence of preeclampsia and gestational hypertension was comparable
between the groups. In the insulin-group, labour was more often induced and more planned caesarean
sections were performed (p = 0.001). Compared with the general obstetric population, the percentage of LGA
neonates was higher in the GDM population (11.0 % vs.19.9 %, p = <0.001).
Conclusions: Neonatal and obstetric outcomes were comparable either with diet-only or additional insulin
therapy. However, compared with the general obstetric population, the incidence of LGA neonates was
significantly increased in this GDM cohort.
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Background
Gestational diabetes mellitus (GDM) is a rising health
problem worldwide and affects up to 14 % of all preg-
nancies, depending on the diagnostic criteria used and
the population studied [1, 2]. GDM increases the risk of
short-term and long-term adverse health outcomes for
both mother and child, including neonatal and obstetric
complications during childbirth and obesity and diabetes
in later life [3–7].
Landmark studies have consistently shown that strict
glycaemic control throughout pregnancy can effectively
improve adverse health outcomes for mother and child
[8–10]. Based on their results, new criteria for screening
and treatment of GDM have been adopted in national
and international guidelines. In the Netherlands, the
Dutch Society of Obstetrics and Gynaecology guideline
“Diabetes and Pregnancy” was revised in 2010 [11]. This
guideline for the screening and treatment of GDM was
largely based on the British National Institute for Health
and Care Excellence (NICE) 2008 guidelines and the
World Health Organization’s (WHO) diagnostic criteria
(1999) for GDM, recommending to screen for GDM in
high-risk women using the 2-h 75-g oral glucose tolerance
test (OGTT) [12, 13]. This new guideline focused on a
more active screening and treatment policy provided by
“usual care” in the preceding years.
To date, the consequences of the guidelines on preg-
nancy treatment and outcomes have not been evaluated
extensively. Moreover, as described in systematic reviews,
most of the earlier studies only compared intensive treat-
ment or any therapeutic intervention for GDM with usual
obstetric care and made no distinction in pregnancy
outcomes for diet-only treatment compared with insulin-
treated women [14–18].
Hence, in this retrospective observational study we
evaluated the neonatal and obstetric outcomes of preg-
nancies complicated by GDM. Screening and treatment –
diet-only versus additional insulin therapy – were based
on the 2010 national Dutch guidelines. We also compared
these GDM outcomes with the general obstetric popula-
tion in the Northern region of the Netherlands.
Methods
Study design and population
This retrospective observational cohort study of women
with GDM was conducted in two hospitals in the North
of the Netherlands, University Medical Center Groningen
and non-university Martini Hospital Groningen. Those
centers adopted a joint protocol on screening and treat-
ment of GDM in January 2011 after revision of the Dutch
guideline in 2010 [11]. The electronic medical files of all
women with a diagnosis of GDM, who visited the out-
patient clinic of both hospitals between January 2011 and
September 2014, were eligible for inclusion in the study.
Pregnant women were tested for GDM if they had risk
factors for GDM according to the Dutch guideline or
signs suggestive of GDM (like foetal macrosomia and/or
polyhydramnion). These GDM risk factors were: previ-
ous GDM, pre-gestational body mass index (BMI)
≥30 kg/m2, previous infant weighing ≥4500 g at birth,
first-degree relative with type 2 diabetes, ethnic origin
(South-Asian, Hindu, Afro-Caribbean, Middle-Eastern,
Morocco, and Egypt), history of intrauterine fetal death,
and history of polycystic ovary syndrome. Pregnant
women with GDM risk factors were routinely screened
for GDM at 24–28 weeks of gestation by their midwife’s
office care, or by their gynaecologist in secondary care.
Women with previous GDM were screened at 16–18
weeks of gestation and when the results were negative,
this was repeated in week 24–28 of gestation.
A 75-g OGTT was used for the screening of GDM.
GDM was diagnosed when fasting plasma glucose was
≥7.0 mmol/l and/or 2-h value ≥7.8 mmol/l after the 75-g
glucose load, according to the diagnostic criteria of the
WHO (1999) [12]. In addition, GDM was diagnosed
without an OGTT if fasting glucose was >7.0 mmol/l or
a random glucose was >11.1 mmol/l.
In total 839 women were diagnosed with GDM and
referred to the diabetes outpatient clinic for treatment.
For the present analysis, women with twin pregnancy (n =
15) or missing pregnancy outcomes (n = 4) were excluded
(Fig. 1). This study is conducted in accordance with the
guidelines of the Declaration of Helsinki and Good Clin-
ical Practice. The study has been exempted for approval
according to the Medical Research Involving Human
Subjects Act [19]. This report is based on patient data
acquired during care-as-usual, the data has been analyzed
retrospectively and all the requirements for patient ano-
nymity are in agreement to the regulations of the ethical
committee of both hospitals for publication of patient
data. According to this and the Dutch law Medical
Research with Human Subjects, no approval from an
ethics committee is necessary.
GDM management
The first step in the management of women with GDM
was dietary advice by a dietician, which included advice
about carbohydrate intake and carbohydrate distribution.
Women were also instructed to measure fasting and 1-h
postprandial blood glucose levels every day. Blood glucose
levels were reviewed after 1–2 weeks. Women with fasting
blood glucose level >5.3 mmol/l and/or post prandial
blood glucose level >7.8 mmol/l received additional
insulin therapy to obtain blood glucose values below these
treatment goals. Insulin was commenced when two blood
glucose results at the same moment of the day were
elevated despite dietary intervention. Insulin treatment
regimens were: long-acting insulin only, prandial short-
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acting insulin or a combination of both (basal-bolus
regimen), depending on the individual glycaemic profile.
In both centres short-acting insulin analogues and Neutral
Protamine Hagedorn (NPH) insulin were used in GDM
treatment.
Women were intensively followed with regular e-mail
and/or telephone contact, at least weekly, in order to
assist them to achieve and maintain the glycaemic tar-
gets. Every 3–4 weeks or on request if indicated, women
visited the diabetes and obstetric outpatient clinics. If
applicable based on self-monitoring of the blood glucose
values, diet was adjusted and insulin dose increased to
maintain blood glucose levels within the target range.
Fetal growth was evaluated by ultrasonography, per-
formed every 4 weeks by trained obstetricians. In both
centres labour was induced at or around 38 weeks in
women on insulin therapy with taking blood glucose
control as well as fetal growth into consideration. Labour
was also induced for non-GDM related maternal or fetal
indications, for instance gestational hypertension or
preeclampsia. The diet- and insulin-treated women were
both followed to the date of delivery and were discussed
every 3 weeks in a multidisciplinary consultation in the
University Medical Center Groningen. In the Martini
Hospital multidisciplinary consultation occurred immedi-
ately after the outpatient clinic visit.
Clinical data collection
All data were collected from electronic medical- and
birth records. Ethnicity was labeled in five categories:
Caucasian, Asian (Indian or South-East Asian), African-
American, Mediterranean (Hispanic, Middle-Eastern,
North-African or South-American), and unknown.
Chronic hypertension was defined as a systolic blood pres-
sure (SBP) ≥140 mmHg, a diastolic blood pressure (DBP)
≥90 mmHg on two occasions at least 4 h apart or the use
of blood-pressure lowering drugs, before pregnancy. Family
history of diabetes was defined as having a first degree
relative who had type 2 diabetes. HbA1c values were
measured by standardized HPLC method on a Tosoh G8
system (Tosoh, Tokyo, Japan), considering 22–42 mmol/
mol (4.2–6.0 %) as normal. The HbA1c values were
measured at the time of GDM diagnosis within 1 week
after the OGTT.
Neonatal outcomes
Neonatal outcomes were a composite outcome of
perinatal complications (still birth/neonatal death, birth
Fig. 1 Flow-chart of the study design. GDM, Gestational Diabetes Mellitus; NPH, Neutral Protamine Hagedorn; SMBG; Self-Monitoring
Blood Glucose
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trauma (shoulder dystocia, fracture of humerus or clav-
icle, brachial plexus injury), neonatal hypoglycaemia and
neonatal hyperbilirubinaemia), gestational age at birth,
birth weight, neonate weighing >4000–4499 g, neonate
weighing >4200 g, neonate weighing ≥4500 g, large for ges-
tational age (LGA) (defined as birth weight above the 90th
percentile, adjusted for gestational age, gender, parity, and
ethnicity [20]), small for gestational age (SGA) (defined as
birth weight below the 10th percentile, adjusted for gesta-
tional age, gender, parity, and ethnicity [20]), Apgar score
<7 at 5 min, need for respiratory support, preterm delivery
(defined as delivery before 37 completed weeks of gesta-
tion), and admission to the neonatology department.
The presence of neonatal hypoglycaemia (occurring >2 h
after birth) was defined as a blood glucose level <2.6 mmol/
l or treatment with a glucose infusion [11]. Neonatal hyper-
bilirubinaemia was recorded when the infant was
treated with phototherapy after birth or admission at
the neonatology department for this reason. Respiratory
support was defined as the need for supplemental oxy-
gen or continuous positive airway pressure after birth.
Obstetric outcomes
The obstetric outcomes were: induction of labour,
delivery type (spontaneous, instrumental (forceps or
vacuum extraction), planned caesarean section and
secondary caesarean section), gestational hypertension,
and preeclampsia.
Gestational hypertension was defined as a SBP
≥140 mmHg and/or a DBP ≥90 mmHg, with no evidence
of pre-existing hypertension and the absence of protein-
uria. Preeclampsia was defined as a combination of gesta-
tional hypertension and proteinuria (≥300 mg/24-h) and
included eclampsia and ‘Hemolysis Elevated Liver en-
zymes and Low Platelets’ (HELLP)-syndrome.
For comparison, the general obstetric population in
the Northern region of the Netherlands and their regis-
tered neonatal and obstetric outcomes during the period
2011–2013 served as a reference population screened
with the same guidelines, these data were provided
from the Dutch Perinatal Registry and the Municipal
Health Service Groningen. Data of the general obstetric
population were available for the following outcomes:
still birth/neonatal death, neonate weighing >4000–
4499 g, neonate weighing ≥4500 g, LGA, SGA, and
Apgar score <7 at 5 min.
Statistical analyses
Continuous data are presented as mean ± standard devi-
ation (SD) or as median and inter quartile range [IQR]
in case of skewed distribution. Categorical data are pre-
sented as number and percentage. Differences between
the groups were tested using Student’s unpaired t-test
for continuous data or Mann-Whitney U Test in case of
skewed distribution. For categorical data Chi-square or
Fisher’s exact test were used.
All P-values are two-tailed, and P-values <0.05 were
considered statistically significant. All analyses were
conducted with the use of the statistical package IBM
SPSS (version 22.0. Armonk, NY: IBM Corp).
Results
The maternal characteristics are summarized in Table 1.
Of the 820 women with GDM, 460 women (56.1 %) met
the glycaemic goals on diet-only and 360 women (43.9 %)
required additional insulin therapy. Of the women who
required additional insulin therapy, 143 women (40 %)
received trice daily pre-prandial short-acting insulin, 165
women (46 %) received basal-bolus insulin therapy and 39
women (11 %) received long-acting insulin therapy to
achieve the glycaemic targets (n = 13 missing data on type
of insulin). The median insulin dose was 22 U/day; IQR
12–42 U/day. All women were monitored and treated
similarly and achieved good glycaemic control.To estab-
lish glycaemic control third trimester HbA1c values were
evaluated (week 32-36 of gestation). For a small sample of
women ( n = 212) the HbA1c values were also measured
in third trimester of their pregnancy. The median HbA1c
values were higher in the insulin-group (n = 125; median
5.7 % (39 mmol/mol), IQR 5.4-6.0 % (36-42 mmol/mol))
compared with the diet-group (n = 87; median 5.5 % (37
mmol/mol), IQR 5.3-5.6 % (34-38 mmol/mol)). The
women in the insulin-group were slightly older and were
more often overweight (BMI ≥25 kg/m2). In addition,
multiparity was higher in the insulin-group and a higher
proportion had a previous GDM, previous infant weighing
≥4500 g at birth, and a family history of diabetes. The
median fasting glucose level and 2-h glucose level after a
75-g OGTT were higher in the insulin-group compared
with the diet-group. In the whole cohort, GDM diagnosis
was based only on the fasting glucose in 1 % during the
OGTT, and 91 % tested positive only on the 2-h value. In
total 9685 women (with a mean maternal age of 30.9 ±
4.9) and 9854 neonates of the Northern region of the
Netherlands served as a reference population.
Neonatal outcomes
Table 2 shows the neonatal outcomes. Between the treat-
ment groups, there were no significant differences in
neonatal outcomes with respect to the perinatal compli-
cations (p = 0.221). Although the frequency of neonatal
hypoglycaemia and neonatal hyperbilirubinaemia tended
to be higher in the insulin-group, these differences were
not statistically significant. For the variable neonatal
hypoglycaemia, neonates born <37 weeks of gestation
with neonatal hypoglycaemia were excluded (n = 7).
Neonates born to women in the insulin-group had a sig-
nificantly lower birth weight (3364 vs. 3467 g, p = 0.005)
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Table 1 Clinical characteristics according to the treatment groups of 820 women with gestational diabetes mellitus
Treatment groups
Characteristics Overall Diet Insulin P-value*
N (%) 820 460 (56.1) 360 (43.9)
Age (years) 32.0 ± 5.1 31.6 ± 4.9 32.6 ± 5.2 0.010
Ethnicity, n (%) NS
Caucasian 658 (80.2) 377 (82.0) 281 (78.1)
Asian 55 (6.7) 35 (7.6) 20 (5.6)
African-American 35 (4.3) 18 (3.9) 17 (4.7)
Mediterranean 57 (7.0) 22 (4.8) 35 (9.7)
Unknown 15 (1.8) 8 (1.7) 7 (1.9)
Family history of DM, n (%) 326 (39.8) 156 (33.9) 170 (47.2) <0.001
History of PCOS, n (%) 40 (4.9) 24 (5.2) 16 (4.4) NS
Previous GDM, n (%) 86 (10.5) 25 (5.4) 61 (16.9) <0.001
Previous infant weighing ≥4500 g at birth, n (%) 90 (11.0) 35 (7.6) 55 (15.3) <0.001
History of IUFD, n (%) 16 (2.0) 5 (1.1) 11 (3.1) 0.043
History of spontaneous abortion, n (%) 223 (27.2) 113 (24.6) 110 (30.6) NS
Chronic hypertension, n (%) 37 (4.5) 15 (3.3) 22 (6.1) NS
Smoking during pregnancy, n (%) 81 (9.9) 42 (9.1) 39 (10.8) NS
Multigravida, n (%) 564 (68.8) 285 (62.0) 279 (77.5) <0.001
Parity, n (%) <0.001
0 333 (40.6) 223 (48.5) 110 (30.6)
1–2 436 (53.2) 216 (47.0) 220 (61.1)
> 2 51 (6.2) 21 (4.6) 30 (8.3)
Pre-gestational BMI, n (%) b <0.001
< 25 kg/m2 260 (32.7) 173 (38.7) 87 (25.0)
25–29.9 kg/m2 231 (29.1) 126 (28.2) 105 (30.2)
≥ 30 kg/m2 304 (38.2) 148 (33.1) 156 (44.8)
Pre-gestational BMI (kg/m2) 27.7 [24.0–31.9] 26.9 [23.3–31.4] 29.2 [25.0–33.4] <0.001
Weight gain mother (kg) a 8.0 [4.0–12.0] 9.0 [5.0–13.0] 7.0 [3.0–11.0] <0.001
Indication for OGTT, n (%) c 0.010
Risk factors 523 (66.2) 275 (62.4) 248 (71.1)
Signs 267 (33.8) 166 (37.6) 101 (28.9)
Fasting glucose level (mmol/l) 5.0 [4.6–5.5] 4.8 [4.5–5.2] 5.3 [4.9–5.9] <0.001
2-h glucose level after a 75-g OGTT (mmol/l) 8.6 [8.1–9.4] 8.5 [8.0–9.1] 8.8 [8.2–9.7] <0.001
Abnormal value only on fasting glucose level, n % 8 (1.0) 3 (0.7) 5 (1.5) NS
Abnormal value only on 2-h glucose level, n % 746 (91.0) 440 (95.7) 306 (85) 0.003
Gestational age at time of OGTT (wks) 27.9 [25.9–30.7] 28.4 [26.7–32.3] 27.1 [24.4–29.3] <0.001
HbA1c d
mmol/mol 37 [34–40] 37 [34–39] 38 [36–42] <0.001
% 5.5 [5.3–5.8] 5.5 [5.3–5.7] 5.6 [5.4–6.0]
Data are expressed as mean ± SD, median [IQR], or proportion n (%)
Abbreviations: BMI Body Mass Index, DM Diabetes Mellitus, GDM Gestational Diabetes Mellitus, IUFD Intrauterine Fetal Death, PCOS Polycystic Ovary Syndrome,
OGTT Oral Glucose Tolerance Test, HbA1c Haemoglobin A1c, wks weeks, g gram, NS not significant
* P-values were based on Student’s unpaired t-test (non-skewed continuous variables), Mann-Whitney U-Test (skewed continuous variables) or chi-square test
(categorical variables)
aWeight gain from pre-pregnancy weight to first visit
bN = 795 due to missing data on weight or height
cN = 790 due to missing data on indication of OGTT
dN = 643 due to missing data. The HbA1c values were measured at the time of GDM diagnosis within 1 week after the OGTT
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and a lower gestational age at birth (38.1 vs. 38.6 weeks,
p = 0.001) compared with neonates born to women in
the diet-group. Moreover, the frequency of neonates
weighing >4000–4499 g were higher in the diet-group
compared with the insulin group (14.0 % vs. 8.8 % p =
0.009). However, birth weight was not different between
the groups when expressed in percentiles (p= > 0.05),
adjusted for gestational age, parity, ethnicity, and gender.
For the variable birth weight, neonates with extreme
prematurity (born <28 weeks) were excluded (n = 3), to
Table 2 Neonatal outcomes according to gestational diabetes mellitus treatment groups
Treatment groups
Outcome variable Overall Diet Insulin P-value* General obstetric population P-value**
N (%) 820 460 (56.1) 360 (43.9) 9854 a
Perinatal complications, n (%) b 75 (9.1) 36 (7.8) 39 (10.8) NS
Still birth/neonatal death, n (%) c 2 (0.2) 0 (0.0) 2 (0.6) NS 89 (0.9) 0.048
Birth trauma, n (%) 30 (3.7) 19 (4.1) 11 (3.1) NS
Hypoglycaemia, n (%) d 28 (3.4) 12 (2.6) 16 (4.5) NS
Hyperbilirubinaemia, n (%) 15 (1.8) 5 (1.1) 10 (2.8) NS
Birth weight (g) e 3422 ± 522 3467 ± 522 3364 ± 517 0.005
Infants >4000–4499 g, n (%) 96 (11.7) 63 (14.0) 32 (8.8) 0.009 1207 (12.2) 0.350
Infants >4200 g, n (%) 40 (4.9) 25 (5.4) 15 (4.2) NS
Infants ≥4500 g, n (%) 10 (1.2) 8 (1.7) 2 (0.6) NS 218 (2.2) 0.059
Birth weight percentiles, n (%) f NS
< 10th percentile 27 (3.3) 19 (4.1) 8 (2.2)
10–20th percentile 44 (5.4) 20 (4.3) 24 (6.7)
20–50th percentile 202 (24.6) 109 (23.7) 93 (25.8)
50–90th percentile 384 (48.6) 214 (46.5) 170 (47.2)
90–95th percentile 67 (8.2) 46 (10.0) 21 (5.8)
> 95th percentile 96 (11.7 52 (11.3) 44 (12.2)
Large for gestational age, n (%) g 163 (19.9) 98 (21.3) 65 (18.1) NS 1082 (11.0) <0.001
Small for gestational age, n (%) h 27 (3.3) 19 (4.1) 8 (2.2) NS 788 (8.0) <0.001
Gestational age at birth (wks) 38.3 [38.0–39.0] 38.6 [38.0–39.6] 38.1 [38.0–38.4] <0.001
Apgar <7 at 5 min, n (%) 27 (3.3) 17 (3.7) 10 (2.8) NS 92 (2.0) 0.009
Respiratory support, n (%) 26 (3.2) 16 (3.5) 10 (2.8) NS
Preterm delivery, n (%) NS
< 28 weeks 3 (0.4) 1 (0.2) 2 (0.6)
28–32 weeks 5 (0.6) 2 (0.4) 3 (0.8)
32–37 weeks 44 (5.4) 25 (5.4) 19 (5.3)
Admission neonatology, n (%) 121 (14.8) 61 (13.3) 60 (16.7) NS
Data are expressed as mean ± SD, median [IQR], or proportion n (%)
Abbreviations: g grams, wks weeks, NS not significant
* P-values were based on Student’s unpaired t-test (non-skewed continuous variables), Mann-Whitney U-Test (skewed continuous variables) or chi-square test
(categorical variables)
** P-values for the GDM population (overall) and general obstetric population were based on chi-square test
a In total n = 9685 mothers with a mean age of 30.9 ± 4.9. Not all of the neonatal and obstetric outcomes in the general population were well reported and this
has resulted in lack of information for some neonatal outcomes
b Perinatal complications included the following: still birth/neonatal death, birth trauma (shoulder dystocia, fracture of humerus or clavicula), hypoglycaemia,
and hyperbilirubinaemia
c One still birth was associated with gestational diabetes and the other still birth was associated with a congenital heart defect
d Hypoglycaemia was defined as neonates without prematurity (born <37 weeks of gestation). There were n = 7 neonates with hypoglycaemia and
prematurity excluded
e Mean birth weight was calculated after exclusion of neonates with extreme prematurity (born <28 weeks of gestation). There were n = 3 neonates with extreme
prematurity (178 days, 185 days, and 195 days)
f Birth weight in percentiles were adjusted for gestational age, gender, parity, and ethnicity
g Large for Gestational Age was defined as a birth weight above the 90th percentile, adjusted for gestational age, gender, parity, and ethnicity
h Small for Gestational Age was defined as birth weight below the 10th percentile, adjusted for gestational age, gender, parity, and ethnicity
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remove the potential bias for extreme low birth weight.
There were no significant differences between the two
groups with respect to LGA, SGA, neonate weighing
>4200 g, neonate weighing ≥4500 g, Apgar score <7 at
5 min, need for respiratory support, preterm delivery,
and admission to the neonatology department.
In comparison, the percentage of LGA neonates with a
birth weight >90th percentile was significantly higher in
the GDM population (19.9 %) compared to the general
obstetric reference population (11.0 %) (p = <0.001). Fur-
ther, the percentage of SGA neonates with a birth weight
<10th percentile was significantly lower in the GDM popu-
lation (3.3 %) compared to the general obstetric reference
population (8.0 %) (p = <0.001). Apgar score <7 at 5 min
was significantly lower in the general obstetric reference
population (2.0 %) compared with the GDM population
(3.3 %) (p = 0.009). There were no differences between the
GDM population and the general obstetric reference popu-
lation with respect to infants weighing >4000–4499 g and
infants weighing ≥4500 g.
Obstetric outcomes
The obstetric outcomes are shown in Table 3. Labour
was induced more frequently in the insulin-group.
However, insulin therapy was one of the indications
to induce labour in both hospitals at or around
38 weeks. There were significantly more planned cae-
sarean sections in the insulin-group compared with
the diet-group (p = 0.001) while secondary caesarean
sections were comparable (p = 0.335). There were
more instrumental vaginal deliveries in the diet-group
(p = 0.052). There were no differences in occurrence
of preeclampsia and gestational hypertension between
the two groups.
Discussion
In this retrospective observational cohort study of 820
singleton GDM pregnancies treated according the
revised national guideline on systematic screening and
treatment of GDM, we found a higher incidence of LGA
neonates of approximately 20 % compared with 11 % in
the general obstetric population in the Northern region
of the Netherlands. However, there were no major differ-
ences in neonatal and obstetric outcomes between
women treated with diet-only and those who needed
additional insulin therapy.
A recent large population-based study investigated the
pregnancy outcomes complicated by pre-existing dia-
betes and GDM in Alberta, Canada [21]. Compared with
our GDM population we found comparable results for
the following adverse pregnancy outcomes, preeclamp-
sia, stillbirth, admission to the neonatology department,
and Apgar score below 7 at 5 min. In the Canadian
study there was a much higher proportion of caesarean
sections performed in the GDM pregnancies compared
with our study (36.9 % vs. 12.1 %). Furthermore, the per-
centage LGA infants was lower in the Canadian GDM
population (15.3 % vs. 19.9 %) and they found a higher
percentage of SGA (9.4 % vs. 3.3 %) infants compared
with our study [21].
Five systematic reviews have summarized the studies
specifically on the effect of treatment of GDM on
pregnancy outcomes [14–18]. They included studies
that compared intensive treatment – including diet
modification, glucose monitoring and/or insulin – or
Table 3 Obstetric outcomes according to gestational diabetes mellitus treatment groups
Treatment groups
Outcome variable Overall Diet Insulin P-value*
N (%) 820 460 (56.1) 360 (43.9)
Induction of labour, n (%) 533 (65.0) 271 (58.9) 262 (72.8) NA a
Delivery type, n (%)
Spontaneous 561 (68.4) 317 (68.9) 244 (67.8) NS
Instrumental b 67 (8.2) 46 (10.0) 21 (5.8) NS
Caesarean section 99 (12.1) 60 (13.0) 39 (10.8) NS
Planned caesarean section 93 (11.3) 37 (8.0) 56 (15.6) 0.001
Preeclampsia, n (%) c 28 (3.4) 16 (3.5) 12 (3.3) NS
Gestational hypertension, n (%) 75 (9.1) 43 (9.3) 32 (8.9) NS
Data are expressed as proportion n (%)
Abbreviations: NS not significant, NA not applicable
* P-values were based on chi-square test for categorical variables
a Not applicable, insulin therapy is one of the indications to induce labour in GDM pregnancy at or around 38 weeks of gestation
b Instrumental is defined as forceps and vacuum extraction
c Preeclampsia included eclampsia (n = 1) and Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome (n = 1)
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any therapeutic intervention of GDM with usual ob-
stetric care in GDM women. It was shown that inten-
sive treatment of GDM reduced the risk of preeclampsia,
shoulder dystocia, and macrosomia. In line with our find-
ings, these reviews reported a low incidence of serious ad-
verse outcomes, like mortality and birth trauma.
In contrast with the landmark trials on treatment of
GDM, the number of LGA neonates in our study was
relatively high [8, 9]. In the Australian Carbohydrate
Intolerance Study (ACHOIS) the prevalence of LGA ne-
onates was 13 % in the treatment group and in the study
by Landon et al. it was 7.1 % [8, 9]. This discrepancy in
the prevalence of LGA neonates can be possibly ex-
plained by the differences in diagnostic criteria for
GDM. Especially, the study by Landon et al., included
women with milder glucose intolerance using the fol-
lowing cut-off values: fasting value <5.3 mmol/l; 1-h
value ≥10.0 mmol/l; 2-h value ≥8.6 mmol/l; and 3-h
value ≥7.8 mmol/l after a 100-g OGTT [8]. Compared
with our study, they included women who had slightly
lower fasting glucose value but higher post GTT value.
Furthermore, different definitions for LGA were used
between the studies. In the Landon study the percent-
age neonates with a birth weight >4000 g was almost
similar with the percentage observed in our GDM
population. However, in the Landon study there was a
small difference between the proportion neonates with a
birth weight >4000 g and the proportion LGA neonates,
as they did not correct for gender, ethnicity and parity [8].
In our study LGA was defined as a birth weight above the
90th percentile, specifically adjusted for gender, parity and
ethnicity [20]. Therefore, we found a larger difference be-
tween neonates weighing >4000 g and LGA neonates.
In 2010 the International Association of the Diabetes
and Pregnancy Study Groups (IADPSG) and in 2013 the
WHO adopted new diagnostic criteria for GDM [22, 23].
The WHO 2013/IADPSG diagnostic criteria for GDM
recommends the following 75-g OGTT glycaemic
thresholds: fasting value ≥5.1 mmol/l; 1-h ≥10.0 mmol/l;
and a 2-h value ≥8.5 mmol/l [22, 23]. In our study the
WHO 1999 [12] diagnostic criteria for GDM were used,
with a much higher fasting glucose threshold. However,
the screening and diagnostic criteria for GDM are incon-
sistent across Europe [24]. The recently revised British
NICE guideline 2015 recommends the following alterna-
tive 75-g OGTT glycaemic thresholds: fasting value
≥5.6 mmol/l; 2-h value ≥7.8 mmol/l [25]. The 2-h glucose
level of the NICE guideline corresponds with our guide-
line for the diagnosis of GDM, only the NICE guideline
proposed a lower fasting glucose value. The NICE guide-
line proposed these thresholds, because of the treatment
costs and the limited evidence for treating at lower diag-
nostic thresholds [25]. Nevertheless, a recent study com-
paring the outcomes among the IADPSG criteria and
NICE 2015 criteria, demonstrated that women who test
positive for GDM according to the IADPSG criteria but
negative for the NICE 2015 criteria, had the highest risk
of having infants with LGA. In other words, the
IADPSG criteria identified women at risk of LGA who
may benefit from treatment, but these women were un-
identified and not treated with the WHO 1999 [12]
guideline and NICE [25] guideline [26]. A similar prob-
lem of too high cut-off value for fasting blood glucose
may hamper the Dutch guideline.
A reduction in the proportion of LGA neonates is an
important treatment target in GDM, since LGA neo-
nates apart from the risk of obstetrical complications are
possible more likely to develop obesity and diabetes in
early adulthood and later life [3, 4]. The more stringent
IADPSG glycaemic thresholds may contribute as they
have been shown to accurately identify women at risk of
delivery LGA neonates [22, 26]. The timing of the diag-
nosis and intervention of GDM is another factor of
concern. GDM screening is advised between 24 and
28 weeks of gestation. In our study the median gesta-
tional age at GDM diagnosis ranged from 26 to 31 weeks,
in a considerable proportion of women, intervention was
started late in pregnancy. The OGTT could be scheduled
more strictly at week 24 or even before week 24. One re-
cent study [27] has shown that despite early testing and
treatment, early GDM diagnosis (<24 weeks) in high-risk
women was associated with adverse pregnancy out-
comes, including LGA neonates. The study indicates
that early identification in high-risk GDM women is im-
portant to improve the pregnancy outcomes [27]. How-
ever, screening for GDM before 24 weeks of gestation
would increase the amount of false negative OGTT’s.
The neonates born in the diet-group and insulin-
group were more likely to be LGA compared with the
general obstetric population in the Northern region of
the Netherlands. It has been shown that LGA is not
always a consequence of hyperglycaemia, other risk
factors such as pre-pregnancy overweight/obesity, mater-
nal weight gain during pregnancy, and maternal age
increases the risk of having a LGA neonate [28–31]. The
women in this GDM cohort were older compared with
the general obstetric population and the percentage of
pre-pregnancy overweight women in our present cohort
was high, almost 70 %, but not higher than the Landon
study [8]. However, a recent meta-analysis has shown
that lifestyle intervention in obese pregnant women
reduces maternal weight gain, but without differences in
LGA or macrosomia [32].
The main strength of this study is that it evaluated the
results of the implementation of the in 2010 introduced
guideline in a large GDM population. It further focuses
on outcomes in diet-only and insulin-treated women.
Therefore the study is indicative for routine clinical
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practice and makes the results more applicable to real-
life clinical care. An additional strength is the compari-
son with data from the general obstetric population in
the same region of the Netherlands.
A theoretical limitation of this study is the retrospect-
ive design. This may have resulted in lack of information
from variables in existing medical and birth records,
however most of the medical and birth records in our
study were complete. A further limitation is that our
national guideline uses the “old” WHO 1999 diagnostic
criteria for GDM which differ greatly from the new
WHO 2013 criteria [12, 23]. On the other hand, for the
treatment of GDM we use the new stringent inter-
national glucose targets to obtain glycaemic control in
GDM pregnancies. At last, not all the neonatal and ob-
stetric outcomes in the general population are available
from public dataset with sufficient detail and this has re-
sulted in lack of information for some neonatal and ob-
stetric outcomes.
Our current GDM guideline on systematic screening
and stringent treatment of GDM was successful in
achieving a low incidence of birth complications
comparable to the literature, but the percentages of LGA
neonates was significantly higher in GDM compared to
other international GDM studies, and to the general
obstetric population. This has practical implications for
the Dutch clinical guideline for GDM that is not optimal
at this moment for reducing LGA neonates. Adopting
stricter diagnostic criteria should be considered in the
next revision of the Dutch guideline, the current criteria
is likely not stringent enough. There is more evidence
from other countries that the more stringent criteria is
associated with significant improvements in pregnancy
outcomes, including lowering the frequency of LGA
neonates [33]. Furthermore, we agree with Benhalima et
al. who ultimately recommend the use of the same diag-
nostic criteria for GDM across Europe [24].
Conclusions
In summary, in this GDM population screened and
treated according to the 2010 national guideline, we found
an elevated percentage of LGA neonates compared with
the general obstetric reference population. Although the
incidence of severe pregnancy outcomes was low. We
found no major differences in neonatal and obstetric out-
comes between GDM women treated with diet-only or
additional insulin. Despite the progress in screening and
treatment of GDM, we suggest an adjustment of the
diagnostic criteria is needed to further improve GDM
outcomes, especially to reduce the risk of LGA neonates
for obesity and diabetes later in life.
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